InvestorsHub Logo
Followers 116
Posts 1878
Boards Moderated 0
Alias Born 11/22/2017

Re: flipper44 post# 302926

Monday, 08/31/2020 3:17:14 PM

Monday, August 31, 2020 3:17:14 PM

Post# of 704533
Flipper44,

I found a Consultation Document from 2018:
“Good Clinical Practice for Advanced Therapy Medicinal Products”

https://ec.europa.eu/health/sites/health/files/files/advtherapies/2018_gcp_atmp_en.pdf

Here is the quote from 2018:

The use of placebo should be scientifically and ethically justified. When invasive procedures are required to administer the ATMP or for the collection/extraction of the cells/tissues, control groups receiving placebo only should not be subjected to a procedure if it presents an unreasonable risk. The risk posed by the procedure should be duly explained in the protocol.



And here is the final version from October 2019:

Placebo: The use of placebo should be scientifically and ethically justified. When invasive procedures are required to administer the ATMP or for the collection/extraction of the cells/tissues, control groups receiving placebo only should not be subjected to a procedure if it presents more than minimal risk and minimal burden. The risk posed by the procedure should be duly explained in the Protocol
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/atmp_guidelines_en.pdf

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News